2025 Q3 -tulosraportti
Vain PDF
41 päivää sitten
Tarjoustasot
Spotlight Stock Market SE
Määrä
Osto
9 995
Myynti
Määrä
8 675
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 547 | NON | SHB | ||
| 4 091 | AVA | ENS | ||
| 10 909 | AVA | AVA | ||
| 3 921 | NON | NRD | ||
| 1 000 | ENS | NRD |
Ylin
1,135VWAP
Alin
1,015VaihtoMäärä
0,1 65 528
VWAP
Ylin
1,135Alin
1,015VaihtoMäärä
0,1 65 528
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Avanza Bank AB | 80 273 | 10 909 | +69 364 | 10 909 |
| Nordnet Bank AB | 16 665 | 4 700 | +11 965 | 0 |
| Nordea Bank Abp | 0 | 5 443 | −5 443 | 0 |
| Svenska Handelsbanken AB | 0 | 12 222 | −12 222 | 0 |
| Skandinaviska Enskilda Banken AB | 1 000 | 24 883 | −23 883 | 0 |
| SSW Market Making GmbH | 0 | 39 781 | −39 781 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| SSW Market Making GmbH | 0 | 39 781 | −39 781 | 0 |
| Skandinaviska Enskilda Banken AB | 1 000 | 24 883 | −23 883 | 0 |
| Svenska Handelsbanken AB | 0 | 12 222 | −12 222 | 0 |
| Nordea Bank Abp | 0 | 5 443 | −5 443 | 0 |
| Nordnet Bank AB | 16 665 | 4 700 | +11 965 | 0 |
| Avanza Bank AB | 80 273 | 10 909 | +69 364 | 10 909 |
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 30.1.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 31.10. | |
| 2025 Q2 -tulosraportti | 31.7. | |
| 2025 Q1 -tulosraportti | 21.5. | |
| 2024 Q4 -tulosraportti | 30.1. | |
| 2024 Q3 -tulosraportti | 31.10.2024 |
Datan lähde: FactSet, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·2 päivää sittenAnswer to CoPilot question: Direct Answer: The two U.S. clinics scheduled for Raypilot® System installations in Q4 2025 have not been publicly named in Micropos Medical’s Q3 2025 report. What is confirmed is that they are described as “two well‑renowned clinics in the USA” and that the installations are being carried out in collaboration with Varian Medical Systems, the world’s leading manufacturer of linear accelerators. 🔍 What We Know Decision taken: Micropos Medical announced in its Q3 2025 interim report that Raypilot® will be installed at two prestigious U.S. clinics. Timeline: Installations are scheduled for Q4 2025. Partnership: The collaboration with Varian Medical Systems strengthens credibility and marketing in the U.S. market. Strategic importance: These installations are part of Micropos’s push to expand Augmented SBRT adoption in North America, where validation from top clinics carries significant weight. 📊 Context Earlier U.S. adoption: In August 2024, Micropos announced its first U.S. order at the Medical University of South Carolina (MUSC), where Dr. David Marshall highlighted Raypilot’s ability to improve accuracy and reduce toxicity. Momentum building: The Q3 2025 report signals that Micropos is moving beyond pilot installations into larger, more influential clinics, supported by Varian’s integration capabilities. Market impact: If these two unnamed clinics report positive outcomes, it could accelerate adoption across other U.S. cancer centers. 🎯 Bottom Line The exact names of the two U.S. clinics have not yet been disclosed publicly, but the installations are confirmed for Q4 2025 and are strategically significant because they involve Varian Medical Systems. This partnership positions Raypilot® for broader U.S. adoption, following the earlier MUSC installation. 👉 Once Micropos releases its Q4 2025 report, the names of the clinics are likely to be revealed.- ·5.12.CEO LOOKS FORWARD TO AN INTENSE Q4 We will have to wait for an answer on how it goes. I will continue to wait, but first, patience will be tested.
- ·23.11.Optimistic scenario Financing: A new share issue in early 2026 is successfully completed, with support from the chairman and major owners. Revenue: Growth continues at the same pace as 2025 (200–300 % YoY). Revenue could reach 15–20 MSEK in 2026. Result: The loss decreases significantly thanks to increased revenues and better cost control. The company could approach break-even in 2027. Market: Clinical acceptance increases, more hospitals and clinics implement the technology. Shareholders: Dilution occurs, but the share value increases if the company shows a clear path towards profitability.
- ·3.11.The next 12 months will be decisive for my part. The potential exists. Having waited this long, I believe it's wrong to exit now, but everyone decides for themselves. I don't let myself be influenced by online chatter but follow what the company does via the company's own information. I see the collaboration with Varian/Siemens as very positive and it increases the opportunities in USA.
·2.11.I believe USA is a difficult market and many companies have to report currency losses. I see and follow Synthetic closely, and selling has been difficult. Companies that succeed must show profit; it's not about pushing future profits forward, because patience doesn't exist for years ahead? Micropos has hoped for a long time - but it's not enough.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
Vain PDF
41 päivää sitten
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 päivää sittenAnswer to CoPilot question: Direct Answer: The two U.S. clinics scheduled for Raypilot® System installations in Q4 2025 have not been publicly named in Micropos Medical’s Q3 2025 report. What is confirmed is that they are described as “two well‑renowned clinics in the USA” and that the installations are being carried out in collaboration with Varian Medical Systems, the world’s leading manufacturer of linear accelerators. 🔍 What We Know Decision taken: Micropos Medical announced in its Q3 2025 interim report that Raypilot® will be installed at two prestigious U.S. clinics. Timeline: Installations are scheduled for Q4 2025. Partnership: The collaboration with Varian Medical Systems strengthens credibility and marketing in the U.S. market. Strategic importance: These installations are part of Micropos’s push to expand Augmented SBRT adoption in North America, where validation from top clinics carries significant weight. 📊 Context Earlier U.S. adoption: In August 2024, Micropos announced its first U.S. order at the Medical University of South Carolina (MUSC), where Dr. David Marshall highlighted Raypilot’s ability to improve accuracy and reduce toxicity. Momentum building: The Q3 2025 report signals that Micropos is moving beyond pilot installations into larger, more influential clinics, supported by Varian’s integration capabilities. Market impact: If these two unnamed clinics report positive outcomes, it could accelerate adoption across other U.S. cancer centers. 🎯 Bottom Line The exact names of the two U.S. clinics have not yet been disclosed publicly, but the installations are confirmed for Q4 2025 and are strategically significant because they involve Varian Medical Systems. This partnership positions Raypilot® for broader U.S. adoption, following the earlier MUSC installation. 👉 Once Micropos releases its Q4 2025 report, the names of the clinics are likely to be revealed.
- ·5.12.CEO LOOKS FORWARD TO AN INTENSE Q4 We will have to wait for an answer on how it goes. I will continue to wait, but first, patience will be tested.
- ·23.11.Optimistic scenario Financing: A new share issue in early 2026 is successfully completed, with support from the chairman and major owners. Revenue: Growth continues at the same pace as 2025 (200–300 % YoY). Revenue could reach 15–20 MSEK in 2026. Result: The loss decreases significantly thanks to increased revenues and better cost control. The company could approach break-even in 2027. Market: Clinical acceptance increases, more hospitals and clinics implement the technology. Shareholders: Dilution occurs, but the share value increases if the company shows a clear path towards profitability.
- ·3.11.The next 12 months will be decisive for my part. The potential exists. Having waited this long, I believe it's wrong to exit now, but everyone decides for themselves. I don't let myself be influenced by online chatter but follow what the company does via the company's own information. I see the collaboration with Varian/Siemens as very positive and it increases the opportunities in USA.
- ·2.11.I believe USA is a difficult market and many companies have to report currency losses. I see and follow Synthetic closely, and selling has been difficult. Companies that succeed must show profit; it's not about pushing future profits forward, because patience doesn't exist for years ahead? Micropos has hoped for a long time - but it's not enough.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market SE
Määrä
Osto
9 995
Myynti
Määrä
8 675
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 547 | NON | SHB | ||
| 4 091 | AVA | ENS | ||
| 10 909 | AVA | AVA | ||
| 3 921 | NON | NRD | ||
| 1 000 | ENS | NRD |
Ylin
1,135VWAP
Alin
1,015VaihtoMäärä
0,1 65 528
VWAP
Ylin
1,135Alin
1,015VaihtoMäärä
0,1 65 528
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Avanza Bank AB | 80 273 | 10 909 | +69 364 | 10 909 |
| Nordnet Bank AB | 16 665 | 4 700 | +11 965 | 0 |
| Nordea Bank Abp | 0 | 5 443 | −5 443 | 0 |
| Svenska Handelsbanken AB | 0 | 12 222 | −12 222 | 0 |
| Skandinaviska Enskilda Banken AB | 1 000 | 24 883 | −23 883 | 0 |
| SSW Market Making GmbH | 0 | 39 781 | −39 781 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| SSW Market Making GmbH | 0 | 39 781 | −39 781 | 0 |
| Skandinaviska Enskilda Banken AB | 1 000 | 24 883 | −23 883 | 0 |
| Svenska Handelsbanken AB | 0 | 12 222 | −12 222 | 0 |
| Nordea Bank Abp | 0 | 5 443 | −5 443 | 0 |
| Nordnet Bank AB | 16 665 | 4 700 | +11 965 | 0 |
| Avanza Bank AB | 80 273 | 10 909 | +69 364 | 10 909 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 30.1.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 31.10. | |
| 2025 Q2 -tulosraportti | 31.7. | |
| 2025 Q1 -tulosraportti | 21.5. | |
| 2024 Q4 -tulosraportti | 30.1. | |
| 2024 Q3 -tulosraportti | 31.10.2024 |
Datan lähde: FactSet, Quartr
2025 Q3 -tulosraportti
Vain PDF
41 päivää sitten
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 30.1.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 31.10. | |
| 2025 Q2 -tulosraportti | 31.7. | |
| 2025 Q1 -tulosraportti | 21.5. | |
| 2024 Q4 -tulosraportti | 30.1. | |
| 2024 Q3 -tulosraportti | 31.10.2024 |
Datan lähde: FactSet, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 päivää sittenAnswer to CoPilot question: Direct Answer: The two U.S. clinics scheduled for Raypilot® System installations in Q4 2025 have not been publicly named in Micropos Medical’s Q3 2025 report. What is confirmed is that they are described as “two well‑renowned clinics in the USA” and that the installations are being carried out in collaboration with Varian Medical Systems, the world’s leading manufacturer of linear accelerators. 🔍 What We Know Decision taken: Micropos Medical announced in its Q3 2025 interim report that Raypilot® will be installed at two prestigious U.S. clinics. Timeline: Installations are scheduled for Q4 2025. Partnership: The collaboration with Varian Medical Systems strengthens credibility and marketing in the U.S. market. Strategic importance: These installations are part of Micropos’s push to expand Augmented SBRT adoption in North America, where validation from top clinics carries significant weight. 📊 Context Earlier U.S. adoption: In August 2024, Micropos announced its first U.S. order at the Medical University of South Carolina (MUSC), where Dr. David Marshall highlighted Raypilot’s ability to improve accuracy and reduce toxicity. Momentum building: The Q3 2025 report signals that Micropos is moving beyond pilot installations into larger, more influential clinics, supported by Varian’s integration capabilities. Market impact: If these two unnamed clinics report positive outcomes, it could accelerate adoption across other U.S. cancer centers. 🎯 Bottom Line The exact names of the two U.S. clinics have not yet been disclosed publicly, but the installations are confirmed for Q4 2025 and are strategically significant because they involve Varian Medical Systems. This partnership positions Raypilot® for broader U.S. adoption, following the earlier MUSC installation. 👉 Once Micropos releases its Q4 2025 report, the names of the clinics are likely to be revealed.
- ·5.12.CEO LOOKS FORWARD TO AN INTENSE Q4 We will have to wait for an answer on how it goes. I will continue to wait, but first, patience will be tested.
- ·23.11.Optimistic scenario Financing: A new share issue in early 2026 is successfully completed, with support from the chairman and major owners. Revenue: Growth continues at the same pace as 2025 (200–300 % YoY). Revenue could reach 15–20 MSEK in 2026. Result: The loss decreases significantly thanks to increased revenues and better cost control. The company could approach break-even in 2027. Market: Clinical acceptance increases, more hospitals and clinics implement the technology. Shareholders: Dilution occurs, but the share value increases if the company shows a clear path towards profitability.
- ·3.11.The next 12 months will be decisive for my part. The potential exists. Having waited this long, I believe it's wrong to exit now, but everyone decides for themselves. I don't let myself be influenced by online chatter but follow what the company does via the company's own information. I see the collaboration with Varian/Siemens as very positive and it increases the opportunities in USA.
- ·2.11.I believe USA is a difficult market and many companies have to report currency losses. I see and follow Synthetic closely, and selling has been difficult. Companies that succeed must show profit; it's not about pushing future profits forward, because patience doesn't exist for years ahead? Micropos has hoped for a long time - but it's not enough.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market SE
Määrä
Osto
9 995
Myynti
Määrä
8 675
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 547 | NON | SHB | ||
| 4 091 | AVA | ENS | ||
| 10 909 | AVA | AVA | ||
| 3 921 | NON | NRD | ||
| 1 000 | ENS | NRD |
Ylin
1,135VWAP
Alin
1,015VaihtoMäärä
0,1 65 528
VWAP
Ylin
1,135Alin
1,015VaihtoMäärä
0,1 65 528
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Avanza Bank AB | 80 273 | 10 909 | +69 364 | 10 909 |
| Nordnet Bank AB | 16 665 | 4 700 | +11 965 | 0 |
| Nordea Bank Abp | 0 | 5 443 | −5 443 | 0 |
| Svenska Handelsbanken AB | 0 | 12 222 | −12 222 | 0 |
| Skandinaviska Enskilda Banken AB | 1 000 | 24 883 | −23 883 | 0 |
| SSW Market Making GmbH | 0 | 39 781 | −39 781 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| SSW Market Making GmbH | 0 | 39 781 | −39 781 | 0 |
| Skandinaviska Enskilda Banken AB | 1 000 | 24 883 | −23 883 | 0 |
| Svenska Handelsbanken AB | 0 | 12 222 | −12 222 | 0 |
| Nordea Bank Abp | 0 | 5 443 | −5 443 | 0 |
| Nordnet Bank AB | 16 665 | 4 700 | +11 965 | 0 |
| Avanza Bank AB | 80 273 | 10 909 | +69 364 | 10 909 |